Ex Vivo Binding Tests of Experimental Radioligands on Human Tissue
Official title: Ex Vivo Evaluation of Experimental Radiolabeled Ligand Binding in Human Tissue Using Autohistoradiography HERO (Human Ex-vivo RadiOligand) Platform
Run by Central Hospital, Nancy, France · NCT07047677 · Data updated 2026-11-12
This study tests how well experimental radioligands bind to human tissue using anonymized samples obtained from surgeries.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 99 Years |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | Central Hospital, Nancy, France Academic / other |
| Locations | 1 site (Vandœuvre-lès-Nancy) |
| Status | Recruiting |
| Started | November 1, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | September 1, 2030 |
| Registry record updated | June 4, 2026 |
| Trial ID | NCT07047677 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Patients who had a surgical resection at Nancy University Hospital after 2019, with anonymized tissue available for research and no opt-out indicated.
✕Probably not a fit
Patients whose tissue is unusable, not traceable, or whose consent was withdrawn would not contribute to potential benefits of the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The HERO project develops an ex vivo screening platform using anonymized human tissues to quickly and ethically assess how experimental ligands fixate in tissue. It employs autohistoradiography to visualize radiolabeled molecules in tissue sections, aiming to improve translatability from bench to clinic while reducing animal use. The approach focuses on early tissue uptake assessment to inform which ligands may be most suitable for diagnostic or therapeutic goals. Only fully anonymized samples from recent surgical resections are analyzed, with strict consent and traceability controls.
Why it matters
Potential benefit: If successful, this approach could improve the selection of radioligands for human use and shorten development timelines while aligning with 3R principles.
How similar studies have gone: Ex vivo human tissue approaches have shown value in predicting radioligand binding, though broader clinical translation remains ongoing and exploratory.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who underwent surgical resection at the Nancy University Hospital after 2019 (Information provided in the welcome booklet or on posters displayed in waiting rooms, mentioning the possible use of data or resection specimens, unless otherwise stated). * No documented objection, in accordance with the MR004 methodology. * Frozen human tissues (slides, blocks, or sections) from surgical resection or biopsy, transmitted by the CRB or the biopathology department. * Samples are fully anonymized before being made available for analysis. Exclusion Criteria: * • Unusable tissue (degraded, insufficient, contaminated, poorly preserved). * Lack of traceability of the material. * Explicit opposition from the patient to the use of their tissue for research.
Where it's running
-
Chru Nancy
Vandœuvre-lès-Nancy, France Recruiting
Study contacts
- Study coordinator: Caroline BOURSIER, MD
- Email: c.boursier@chru-nancy.fr
- Phone: (0)383154039
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.